{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-015138","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.973427+00:00","generated_at":"2026-06-21T21:57:08.983603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palatin Q1 FY2023 net loss $8.3M; Vyleesi revenue up 445% YoY; PL9643 topline Q2 2023","bullets":["Net loss of $8.3M ($0.86/share) vs $7.1M ($0.75/share) in prior year quarter.","Vyleesi net product revenue $869,654, up 445% YoY; prescriptions dispensed up 17% QoQ.","Phase 3 PL9643 for dry eye: DMC recommends 350-patient study; topline data expected Q2 2023.","Phase 2 oral PL8177 for ulcerative colitis commenced; interim analysis Q1 2023, topline Q3 2023.","Cash $21.2M as of Sep 30; closed $10M offering in Nov 2022; operating cash runway through CY 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-015138","json":"https://secwatch.observer/filing/0001654954-22-015138.json","markdown":"https://secwatch.observer/filing/0001654954-22-015138.md","text":"https://secwatch.observer/filing/0001654954-22-015138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/0001654954-22-015138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:57:08.983603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5045b997fdc8af167057a7826a4d5bf3d7367cd","claim":"PALATIN TECHNOLOGIES INC reported fiscal first quarter ended September 30, 2022 results: revenue $2.3 million, net income $8.3 million, EPS $(0.86) per common share.","evidence_excerpt":"as of June 30, 2022. · Vyleesi® (bremelanotide injection) for the treatment of Hypoactive Sexual Desire Disorder (HSDD): Gross product sales to pharmacy distributors amounted to $2.3 million, while net product revenue increased 13% and prescriptions dispensed increased 17%, over the prior quarter. 1 Business Highlights and Recent Updates · Anti-Inflammatory /","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/0001654954-22-015138-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.3 million"},{"label":"Net income","value":"$8.3 million"},{"label":"EPS","value":"$(0.86) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}